London-based early-stage investment firm AlbionVC has announced the appointment of Dr. Molly Gilmartin to its health tech investment team. With a focus on B2B software, deep tech, and healthcare startups, Dr. Gilmartin’s experience and medical background is expected to augment and strengthen the firm’s position on the latter. She is the sixth woman to join the fund in just over a year and is now the fifth female investor operating within the software and life sciences team.
In joining AlbionVC, Dr. Gilmartin’s journey goes full circle, as she was a founding member of portfolio company Pando, a workflow and messaging tool for doctors, serving as Head of Community.
“I first got to know AlbionVC five years ago when fundraising with Pando, and today I am delighted to join the team. AlbionVC has established itself as a European leader in digital health over the past 20 years. It has both a deep understanding of the landscape, and a proven track record of supporting entrepreneurs in bringing transformational health tech solutions to market,” commented Dr. Gilmartin.
Now joining the firm from McKinsey & Company where she served as an associate, Dr. Gilmartin’s unique background will only further strengthen Albion’s position in the healthcare sector, as her CV includes experiences as Chief Commercial Officer at Induction Healthcare Group and a Clinical Entrepreneur with NHS England.
“I’ve seen, first-hand, the challenges healthcare groups face, and how an innovative approach to solving these challenges can have a huge impact across the board. I can’t wait to uncover and work with the next generation of founders making such impacts in my role as health tech Investor at AlbionVC,” she added.
"I am delighted that Molly has decided to join the AlbionVC health tech investment team. Molly's roles in leadership positions within health technology companies, on the healthcare frontline as a medical doctor and as a consultant provide her with a unique experience and skillset to find and support the next generation of healthcare disruptors in Europe,” concluded healthcare partner Reudig.